Lung Cancer Clinical Trial

Neoadjuvant Immunotherapy in Advanced NSCLC

Summary

A number of clinical trials have demonstrated the efficacy of immunotherapy prior as neoadjuvant therapy. This study evaluates whether said neoadjuvant immunotherapy may improve improve progression free survival in NSCLC. One such example would be to evaluate either single agent or an immunotherapy combination with chemotherapy. Following this, analysis of biomarkers will be conducted to provide personalization in one's regimen.

View Full Description

Full Description

A number of clinical trials have demonstrated the efficacy of immunotherapy prior as neoadjuvant therapy. This study evaluates whether said neoadjuvant immunotherapy may improve improve progression free survival in NSCLC. [The Power Life Sciences Investigative Team](https://www.withpower.com) is running a study to evaluate either single agent or an immunotherapy combination with chemotherapy. Patients can contact a site administrator via the information below, or enroll directly via https://www.withpower.com/trial/phase-4-2019-e67c1. Following this, analysis of biomarkers will be conducted to provide personalization in one's regimen.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

>= 18 Years of Age
Informed consent is provided
Histologically confirmed resectable non-small cell lung cancer with stage II-IIIA (TNM 8th edition)
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Epidermal growth factor receptor (EGFR) mutation negative and anaplastic lymphoma kinase (ALK) translocation negative

Exclusion Criteria:

EGFR mutation positive and ALK translocation positive
Active central nervous system (CNS) metastases
Autoimmune diseases
Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
Patients with interstitial lung disease will not be included if they have symptomatic interstitial lung disease (ILD) - Grade 3-4
Women who are breast feeding or pregnant
Sexually active women or men of childbearing potential who are not willing to use an effective contraceptive method during the study

Study is for people with:

Lung Cancer

Estimated Enrollment:

10

Study ID:

NCT05137912

Recruitment Status:

Not yet recruiting

Sponsor:

Power Life Sciences Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Power Life Sciences
San Francisco California, 94107, United States More Info

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Estimated Enrollment:

10

Study ID:

NCT05137912

Recruitment Status:

Not yet recruiting

Sponsor:


Power Life Sciences Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider